SYKNYSEhealth care

Stryker Corporation

$331.45Up+1.67 (+0.51%)

Research reviewed: Jul 12, 2026, 12:00 AM UTC

Research overview

Stryker Corporation operates in Health Care Equipment within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

Open: 330.18
High: 335.96
Low: 329.10
Market Cap: 127.06B
P/E Ratio: 38.36
52 Week High: --
Dividend: 1.070%
Quarterly Dividend: --

3-month price context

The chart shows the recent 3-month trend so users can understand short-term market structure before opening the full research workspace.

Investment thesis

Base case: Robotic placements can pull through implants, disposables and service revenue while deepening surgeon adoption. The base case remains conditional on supply and manufacturing staying manageable.
Bull case: Robotic placements can pull through implants, disposables and service revenue while deepening surgeon adoption. Healthy elective procedure volumes can sustain demand across hips, knees, trauma and surgical equipment. New implants, neurovascular tools and operating-room technologies can extend share gains.
Bear case: Component shortages, quality issues or sterilization constraints could disrupt high-demand product availability. Budget pressure can delay purchases of robots, beds and other capital equipment. Frequent portfolio additions can raise integration, valuation and management-attention risk.

Key catalysts

Mako installed base
Robotic placements can pull through implants, disposables and service revenue while deepening surgeon adoption.
Procedure growth
Healthy elective procedure volumes can sustain demand across hips, knees, trauma and surgical equipment.
Product innovation
New implants, neurovascular tools and operating-room technologies can extend share gains.

Principal risks

Supply and manufacturing
Component shortages, quality issues or sterilization constraints could disrupt high-demand product availability.
Hospital capital budgets
Budget pressure can delay purchases of robots, beds and other capital equipment.
Acquisition execution
Frequent portfolio additions can raise integration, valuation and management-attention risk.

Latest earnings research

Q1 2026

Stryker's first-quarter 2026 results reflected continued demand across MedSurg, Neurotechnology and Orthopaedics, supported by procedure volumes, capital equipment and product innovation.

Valuation interpretation

The installed-base model supports premium quality when robotic placements translate into recurring implant and service pull-through.
Procedure resilience should be assessed alongside hospital capital cycles and ongoing acquisition requirements.

Peer research

ABT BSX ISRG

Continue in the research workspace

Keep SYK in context, run a multi-agent analysis, and monitor thesis changes.

Analyze SYK free

Explore the full research system

Each stage has a distinct job and leaves an auditable output for the next.

Research methodology Read market reports

Stryker Corporation

3-month price context

Key catalysts

Principal risks

Latest earnings research

Valuation interpretation

Peer research

Recent news

ISRG to Report Q2 Results Next Week: Should You Buy the Stock Now?

Stryker (SYK) Stock Loses Russell Growth Slots As Active Investors Step In

Stryker's Quarterly Earnings Preview: What You Need to Know

Mixed Drivers Fuel Optimism in Stryker Corporation’s (SYK) Performance

The Wide Chasm Priced Into Boston Scientific Stock

Continue in the research workspace

Explore the full research system

Just How Much Risk Is Built Into ISRG Stock?

Data and research sources

Continue researching this stock